Blood Proteomics Unmasks Immune and ECM Dysfunction at the Root of Hypermobile EDS

Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of EDS, affecting an estimated 1 in 500 people, predominantly women. Despite its prevalence, hEDS remains the only EDS subtype without an identified causative gene, making diagnosis entirely clinical and often delayed by years. To address this critical knowledge gap, researchers from the Medical University of South Carolina conducted the first plasma-based proteomic study of hEDS, aiming to characterize the molecular landscape of the disease and identify candidate biomarkers.

The study enrolled adults with clinically diagnosed hEDS meeting 2017 International Criteria alongside age- and sex-matched healthy controls. Blood plasma was collected and analyzed using label-free quantitative mass spectrometry. Bioinformatic tools including pathway enrichment analysis (Gene Ontology, KEGG), volcano plots, and protein-protein interaction networks were applied to interpret differentially expressed proteins. The dataset represented hundreds of plasma proteins, enabling a broad systems-level view of disease-associated proteome changes.

The most striking finding was a pronounced upregulation of complement system proteins—including C3, C4, and downstream effectors—alongside elevated acute-phase response proteins such as fibrinogen chains and alpha-2-macroglobulin. This strongly implicates chronic, low-grade systemic inflammation and innate immune dysregulation as features of hEDS rather than incidental comorbidities. Concurrently, several structural ECM proteins were found to be significantly downregulated, consistent with impaired connective tissue integrity and remodeling capacity. Coagulation cascade proteins were also disrupted, which may explain the easy bruising and vascular fragility frequently reported by hEDS patients.

Pathway analysis highlighted dysregulation in ECM-receptor interaction, complement and coagulation cascades, and acute inflammatory response pathways. Protein-protein interaction network mapping revealed densely connected hubs involving fibronectin, complement C3, and albumin-associated proteins, suggesting these may be central nodes in hEDS pathophysiology. The authors propose that immune activation—potentially triggered by chronic mechanical tissue stress releasing damage-associated molecular patterns—could perpetuate a cycle of inflammation and ECM degradation.

These findings carry significant implications. First, they provide the first molecular evidence supporting an inflammatory and immune component to hEDS, reshaping how clinicians should conceptualize and potentially treat the disease. Second, the identified proteins represent candidate biomarkers for a condition currently lacking any objective diagnostic test. Third, pathways such as complement activation or specific ECM remodeling enzymes may be actionable therapeutic targets. Limitations include a modest sample size, cross-sectional design, and reliance on plasma rather than tissue proteomics, which may miss local connective tissue changes. Replication in larger, independent cohorts is needed before clinical translation.